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Abstract
Background: VSL#3 is a patented probiotic for which several clinical trials suggest benefits on 
motor function, bloating and symptoms of irritable bowel syndrome (IBS).
Objectives: To quantify effects of VSL#3 on abdominal pain, stool consistency, overall 
response, abdominal bloating, and quality of life (QOL) in IBS through meta-analysis.
Methods: MEDLINE (OvidSP and PubMed), EMBASE, Web of Science, and Scopus were 
searched up to May 2017. Using a fixed effects model, we pooled data from intention-to-treat 
analyses of randomized trials (RCTs) comparing VSL#3 to placebo in IBS. Data were reported as 
relative risk (RR), overall mean difference (MD) or standardized MD (SMD) with 95% confidence 
intervals (CI). Quality of evidence was rated using the GRADE approach.
Key Results: Among 236 citations, five RCTs (243 patients) were included. No significant 
differences were observed for abdominal pain (SMD = −0.03; 95% CI −0.29–0.22), bloating 
(SMD = −0.15; 95% CI −0.40–0.11), proportion of bowel movements with normal consistency 
(overall MD = 0; 95% CI −0.09–0.08), or IBS-QOL (SMD = 0.08; 95% CI −0.22–0.39). VSL#3 
was associated with a nearly statistically significant increase in overall response (RR=1.39; 95% 
CI 0.99–1.98).
Conclusions & Inferences: In this systematic review and meta-analysis, there was a trend 
towards improvement in overall response with VSL#3, but no clear evidence effectiveness for IBS. 
However, the number and sample sizes of the trials are small and the overall quality of evidence 
for three of the five outcomes was low. Larger trials evaluating validated endpoints in well-defined 
IBS patients are warranted.
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VSL#3 is a patented probiotic for which several clinical trials suggest benefits on symptoms of 
irritable bowel syndrome (IBS). In the current systematic review and meta-analysis, we were 
unable to demonstrate clear evidence for benefit with VSL#3 in IBS, although a strong trend 
towards improvement in overall response was observed. Further study of VSL#3 in well-defined 
IBS patients using validated clinical endpoints is required.
Keywords
irritable bowel syndrome; probiotic; systematic review; VSL#3
Irritable bowel syndrome (IBS) is a common functional bowel disorder with estimated 
regional prevalence rates ranging from 5.8 to 17.5%.1 The complex pathophysiology of IBS 
remains incompletely understood, but may involve both central and peripheral mechanisms 
including alterations in the brain-gut axis, gastrointestinal (GI) motility, intestinal 
permeability, local immune responses, low-grade inflammation, visceral hypersensitivity and 
intestinal microbiota.2 With increasing evidence linking the intestinal microbiota with 
numerous human syndromes and diseases including IBS,3 there has been growing interest in 
modulation of the microbiota as a therapeutic strategy for IBS. The intestinal microbiota 
may serve as a key factor in IBS pathophysiology through direct effects on the 
aforementioned central and peripheral mechanisms, and through their production of 
microbial metabolic products.4, 5 Composition of the human intestinal microbiota is shaped 
by various host-specific and environmental factors.5, 6 Thus, antibiotic and probiotic 
therapies have been considered as potential treatments to target the intestinal dysbiosis or 
microbial imbalance that may exist in IBS.
Probiotics are live microorganisms that when consumed by the host in adequate amounts, 
may confer beneficial health effects.7 Probiotics have long been used in the treatment of 
many GI symptoms. They are easily available and have been extensively studied. 
Unfortunately, most studies have been of suboptimal quality with significant heterogeneity 
in study endpoints and methodological rigor. A prior systematic review of probiotics in IBS 
reported evidence for efficacy on persistent symptoms, global IBS and abdominal pain 
scores. However, evidence for benefit with individual strains or specific combinations was 
not shown.8 Preclinical studies have demonstrated strain-specific effects of probiotics, which 
should be taken into consideration when prescribing probiotics in the clinical setting.9
Several strains and combinations of strains are currently available for IBS therapy, with 
Lactobacillus sp. and Bifidobacterium sp.8, 9 most frequently studied. A specific probiotic 
combination, VSL#3, is a patented probiotic preparation consisting of eight different strains 
of bacteria (Bifidobacterium longum, B. infantis, B. breve, Lactobacillus acidophilus, L. 
casei, L. delbrueckii ssp.bulgaricus, L. plantarum and Streptococcus salivarus ssp. 
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thermophilus) that has demonstrated efficacy in IBS patients with reduction of bloating and 
abdominal symptoms.10–15 However, studies have generally been small and of limited 
duration. Furthermore, only a few have employed rigorous methodological standards 
utilizing FDA responder endpoints. The objectives of this systematic review are to examine 
clinical efficacy of the patented probiotic VSL#3 on outcomes of abdominal pain, stool 
consistency, overall response, bloating and quality of life (QOL) in patients with IBS.
METHODS
Search strategy and study selection:
The study was conducted and reported in accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses.16 A search of the medical literature was conducted 
in May 2017 using MEDLINE (OvidSP and PubMed interfaces), EMBASE, Web of 
Science, and Scopus by an experienced medical librarian (JH) with input from study 
investigators. Studies were identified using a search strategy that included relevant keywords 
and Medical Subject Headings (MESH) to retrieve randomized controlled trials of VSL#3 
for patients with IBS. A focus on treatment outcome and impact on abdominal pain and 
bowel function was also included. The search strategy contained a combination of MESH 
terms and keywords that included terms related to “Irritable Bowel Syndrome”; “Probiotics” 
OR “VSL #3.mp”; “Treatment outcome” OR “Abdominal Pain”.) The search strategy is 
shown in the Appendix. Randomized trials (RCTs) comparing VSL#3 with placebo among 
patients with IBS were eligible for inclusion. No date limitations or language restrictions 
were applied. All trials were eligible for inclusion regardless of publication-type. First 
period data from cross-over studies were eligible for inclusion. Abstracts and titles identified 
from the search strategy were assessed by two independent investigators (AS and MC) for 
eligibility. All potentially relevant studies were subsequently obtained for a full-text review. 
Bibliographies of eligible studies, available reviews, and clinicaltrials.gov were reviewed. 
Conference abstracts and clinicaltrials.gov were manually searched to identify potentially 
eligible studies. Conflicting decisions were resolved by discussion.
Eligibility criteria:
Eligible for inclusion were randomized placebo-controlled trials examining effects of 
VSL#3 on outcomes of abdominal pain and stool consistency in patients with IBS. Any 
definition of IBS, including physician diagnosis or symptom-based diagnostic criteria, was 
satisfactory for inclusion. Studies investigating patients with other organic gastrointestinal 
conditions including inflammatory bowel disease, microscopic colitis, celiac disease, or 
infectious colitis were excluded. No minimum duration of therapy was applied. Studies had 
to report data on at least one of the primary outcomes: abdominal pain or stool consistency.
Study Outcomes:
The primary outcomes were effects of VSL#3 on mean improvements in abdominal pain and 
stool consistency. Secondary outcomes were effects of treatment on overall response, 
abdominal bloating, and quality of life (QOL). We also assessed the frequency and types of 
adverse events. Outcomes were selected based on previous recommendations established by 
the FDA for evaluating treatment benefit in clinical trials of IBS.
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Data abstraction:
All data were abstracted independently by two investigators (AS and MC) for the primary 
and secondary outcomes on to a Microsoft Excel spreadsheet. Authors of included studies 
were contacted for missing data; their provided responses were included in the analyses. 
Data were recorded as continuous for: (a) mean improvement in abdominal pain scores from 
baseline, (b) proportion of stools with normal consistency while on treatment, (c) mean 
improvement in abdominal bloating scores from baseline, (d) mean improvement in QOL 
scores from baseline. Data were recorded as dichotomous outcomes for overall response, 
defined as proportion of patients achieving a pre-specified endpoint (e.g. satisfactory relief 
in bloating or IBS symptoms) in weekly response for 50% of treatment weeks. Total number 
of adverse events were recorded. Data were abstracted from each trial to assess study 
characteristics: location, number of centers, year published, intervention type, control type, 
dose and duration of therapy, and duration of follow-up. Patient characteristics including 
study population, total number of participants, mean age, and proportion of female patient 
were recorded. Data were also abstracted by two investigators (AS and MC) to evaluate 
individual study risk of bias according to the Cochrane Risk of Bias Assessment Tool17 with 
disagreements resolved by discussion. A third investigator (TI) was available to manage any 
disagreements if they could not be resolved by discussion.
Quality of Evidence:
We used the GRADE approach to evaluate strength of the body of evidence. In this 
approach, level of evidence is rated as high, moderate, low, or very low based on the 
following factors: (1) risk of bias, (2) indirectness, (3) unexplained heterogeneity or 
inconsistency, (4) imprecision, and (5) probability of publication bias. All factors were 
considered for each outcome, and were classified as “serious” or “very serious” if a reason 
could be found for downgrading the evidence.
Data synthesis and statistical analysis:
We used an intention-to-treat analysis for all dichotomous outcomes with dropouts 
categorized as non-responders. Continuous outcomes were recorded using all available data. 
Data were pooled using fixed effects models. Pooled estimates of treatment effect for 
continuous variables were reported as standardized mean difference (SMD) or mean 
difference (MD) with 95% confidence intervals (CI). Proportion of overall responders was 
reported as risk ratio (RR) with 95% CI using the Mantel-Haenszel method. For continuous 
outcomes, we analyzed the mean difference in change from baseline. If this variable was not 
reported and could not be calculated from other data, we used the mean difference at follow-
up. We assessed statistical heterogeneity using the I2 statistic. The I2 statistic represents the 
proportion of variation across studies that is due to differences between studies beyond 
chance. I2 > 50% indicates significant heterogeneity among studies.18
Meta-analyses were performed using the “meta” package19 in R Statistical Software (version 
3.4.2) and the significance level set to an alpha of 0.05. When no standard deviation (SD) 
was reported (Wong et al 2015), it was imputed from other studies using the same scale. 
When a specified endpoint of interest (e.g. proportion of patients achieving a pre-specified 
endpoint in weekly response for 50% of treatment weeks) was not provided (Staudacher et al 
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2017), but data on a similar endpoint were reported, these data were recorded as “surrogate” 
outcomes and pooled for the meta-analysis. We performed additional pre-specified 
sensitivity analyses to assess the effect of VSL#3 by excluding studies with SD imputation 
or a surrogate outcome.
RESULTS
Study Characteristics:
The search strategy used (Appendix) identified 236 citations, of which five RCTs including 
243 patients (124 randomized to VSL#3 and 119 randomized to placebo) were eligible for 
inclusion. A flow diagram of studies identified in the search is shown in Figure 1. 
Characteristics of included studies are summarized in Table 1. Mean age among all study 
participants was 38.3 years (SD=16.2); 69% were women. The trial populations included 
patients with IBS using Rome II or III criteria. Two studies enrolled only patients with 
diarrhea-predominant IBS.11, 13 Patients were screened for prior antibiotic-use which was 
disallowed during the 2 weeks,12, 13 1 month10, 15 or 3 months11 preceding initiation of 
study procedures. Adverse events were recorded in all studies. All five studies were double-
blinded, randomized, placebo controlled trials of VSL#3 doses of 450 billion lyophilized 
bacteria/day10 or 900 billion bacteria per day11–13, 15. Treatment duration ranged from 4 
weeks15, to 8 weeks11–13. Three studies included a 2-week run-in phase.10, 12, 13 One study 
required an amendment to the protocol after 17 participants completed 8 treatment weeks to 
allow for a 2-week run-in phase followed by a 4-week treatment phase due to difficulties 
with patient recruitment.12 One study randomized patients to a co-intervention of sham diet 
vs. low FODMAP diet.15
Quality of Evidence:
Quality of evidence is summarized in Table 2 using the GRADE approach as described in 
the methods. Two studies were considered to be at moderate 10 or high risk of bias 11 due to 
concerns for selection and reporting bias, and evidence was rated down for outcomes in 
which these studies were included. Overall, there was high certainty suggesting a lack of 
benefit on stool consistency and moderate certainty suggesting a trend towards benefit in 
overall response with VSL#3. For all other outcomes, there was low certainty suggesting 
lack of benefit of VSL#3.
Primary Outcomes
Abdominal pain: Four trials10, 12, 13, 15 appraised pain symptoms based on a 100 mm 
visual analogue scale. One trial11 used the Gastrointestinal Symptom Rating Scale (GSRS), 
a clinical rating scale for IBS.20. Overall, no significant difference was observed for mean 
improvement in abdominal pain between VSL#3 (SMD = 0.03; 95% CI −0.22 to 0.29) and 
placebo (Figure 2). No significant statistical heterogeneity was observed across studies (I2 = 
0%, P-value for Cochrane’s Q = 0.7). Sensitivity analysis excluding one study that required 
the use of imputed data for the SD of the abdominal pain intensity score10 showed similar 
findings (SMD = 0.07; 95% CI −0.21 to 0.34). There was no observed heterogeneity among 
studies (I2 = 0%, P=0.6).
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Stool consistency: Data for change in percentage of bowel movements with normal stool 
consistency before and after treatment was available for 177 patients in three studies.12, 13, 15 
There was no significant difference in the change of the proportion of bowel movements 
with normal consistency (Figure 3) for VSL#3 vs. placebo (overall MD = 0; 95% CI= −0.09 
to 0.08). There was no observed heterogeneity across studies (I2 = 0%, P= 0.71).
Secondary Outcomes
Overall response: Data for overall response and proportion of stools with normal 
consistency were available for 177 patients in three studies.12, 13, 15 Two studies defined a 
response as achieving a pre-specified endpoint (e.g. satisfactory relief in bloating or IBS 
symptoms) during at least 50% of the treatment weeks.12, 13 A third study defined overall 
response as adequate relief of symptoms over the past 7 days at the end of the follow-up 
period.15 Relative to the placebo group (32 of 88 [36%] responders), 45/89 (50%) of patients 
treated with VSL#3 reported an overall response (RR=1.39; 95% CI 0.98 to 1.96) (Figure 4). 
There was no significant heterogeneity across studies (I2 = 0%, p = 0.63). Sensitivity 
analysis excluding the trial with overall response defined over the past 7 days demonstrated 
no significant difference in overall response (RR=1.18; 95% CI 0.66 to 2.13) with no 
significant heterogeneity across studies (I2 = 0%, p = 0.48).
Abdominal bloating: Among the five studies, no significant difference was observed for 
mean improvement in abdominal bloating (Figure 5) with VSL#3 vs. placebo (SMD = 0.15; 
95% CI −0.11 to 0.4). There was no significant heterogeneity across studies (I2 = 5%, p = 
0.38). Sensitivity analysis excluding one trial10 for which data imputation was required 
showed similar results (SMD= 0.16; 95% CI −0.12 to 0.44) with no significant heterogeneity 
across studies (I2 = 28%, p = 0.25).
Quality of Life: Data for QOL were available from three studies.10, 11, 15 No significant 
differences (Figure 6) between VSL#3 and placebo treated groups were observed for mean 
improvement in QOL (SMD = −0.08; 95% CI −0.39 to 0.22). There was no significant 
heterogeneity across studies (I2 = 0%, P = 0.65). Sensitivity analysis excluding trial10 with 
imputed data showed similar results (SMD = −0.14; 95% CI −0.49 to 0.21) and 
heterogeneity remained non-significant (I2 = 0%, P = 0.48).
Adverse Events: Only one study15 reported adverse events, which included worsened GI 
symptoms, in 7.8% of placebo patients and 3.8% of VSL#3 patients.
DISCUSSION.
Although individual trials have shown evidence for benefit with VSL#3 vs. placebo for 
abdominal bloating and flatulence, there are no clear data demonstrating improved bowel 
function, pain reduction, or overall response. Few trials have incorporated at least 8 weeks of 
study treatment and study endpoints of interest. In recent years, the FDA has put forth 
recommendations21 to guide trial design and trial endpoints in IBS clinical trials in attempts 
to enhance reliability in assessment of treatment effects. Recommendations for evaluating 
treatment response have focused on “overall response” defined as a pre-specified 
improvement in weekly or daily response for at least 50% of treatment weeks. Additionally, 
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both abdominal pain and stool frequency have been evaluated for response. Consequently, 
guidance for clinicians and patients regarding effective use of probiotics such as VSL#3 in 
treatment of IBS has been vague. Thus, we attempted to assess pooled effects of VSL#3 on 
abdominal pain, stool consistency, and overall response. In this systematic review and meta-
analysis of randomized controlled trials, we were unable to demonstrate clear evidence for 
efficacy of VSL#3 compared to placebo among patients with IBS for any of the outcomes 
examined, with the exception of a nearly statistically significant difference in overall 
response between treatment groups. This lack of effect is generally consistent with findings 
reported in individual studies as well as a prior systematic review of probiotics in IBS, in 
which subgroup analysis of three trials using VSL#3 in IBS showed no significant benefit 
compared to placebo on global or abdominal pain scores.8 At the same time, few adverse 
events were reported, and VSL#3 appears to be safe and well tolerated in IBS.
The precise mechanisms by which VSL#3 exerts potentially beneficial effects are unknown. 
In vivo and in vitro studies have suggested that VSL#3 may modulate host-immune 
response, intestinal microbiota, anti-inflammatory pathways, visceral pain responses and 
epithelial barrier function.22–26 Mechanistic studies exploring potential beneficial effects of 
VSL#3 in patients with IBS have been limited, among which are the trials included in this 
analysis. In both studies by Kim et al,12, 13 investigators incorporated assessment of colonic 
transit to demonstrate retardation of colonic transit in patients treated with VSL#3 in the 
second, but not the first trial. Data on effects of VSL#3 on the intestinal microbiota of IBS 
patients has also been conflicting. Michail et al.11 could not detect any significant changes in 
total or relative composition of gut microbiota after treatment with VSL#3 and placebo, 
while a recent study examined effects of VSL#3 on intestinal microbiota from rectal 
biopsies of IBS patients to demonstrate significant reductions in Bacteroides compared to 
controls.27. Others have examined VSL#3 effects on rectal pain thresholds in IBS and 
association with salivary melatonin to demonstrate significant increases in rectal distension 
pressure thresholds with VSL#3, but not after placebo and significant increases in morning 
melatonin in males treated with VSL#3 but not females.10 Hence, the mechanistic rationale 
promoting use of VSL#3 remains an area of ongoing investigation. Further study to clarify 
the effect of VSL#3 on regulation of pathophysiologic pathways of IBS may be necessary to 
identify specific biomarkers that may predict therapeutic response or guide patient selection 
in future clinical trials, particularly given the heterogeneous nature of IBS. In a recent 
systematic review,28 VSL#3 was associated with a benefit over placebo in inducing 
remission in active ulcerative colitis, implying that probiotics and specific probiotic 
combinations may be effective in this particular patient subset. Enrichment of future IBS 
cohorts with clearly defined patient phenotypes may be helpful in defining the role of 
VSL#3 or other specific probiotics combinations in the treatment of this condition.
Although the results of our systematic review and meta-analysis could not demonstrate a 
clear benefit of VSL#3 compared to placebo, our ability to detect significant differences may 
have been affected by several factors. Limitations of this study are: 1) inclusion of multiple 
IBS subtypes in individual trials for which we were unable to perform subgroup analyses 
due to the small number of total patients and lack of access to individual patient data (which 
was obtained for only two trials)12,13; 2) availability of only five published trials with a 
small number of total participants; 3) variable treatment duration across studies, and; 4) 
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inconsistent reporting of outcomes. Due to the small number of studies, non-significant 
results for assessment of heterogeneity cannot be interpreted as evidence for study 
homogeneity.
The inclusion of multiple IBS subtypes may have obscured the ability to detect the benefit of 
VSL#3, which may have differential effects on IBS subtypes due diverse mechanisms. It is 
hypothesized that probiotics may affect gastrointestinal symptoms through modulation of the 
gut microbiota and there have now been several studies to suggest that specific microbial 
perturbations are associated with bowel pattern phenotype. For example, increased gut 
microbial richness has been associated with longer colon transit29 while decreased species 
richness has been associated with looser stool30. In the study by Kim et al. 200512, VSL#3 
slowed colonic transit relative to placebo in patients with IBS. Based on these observations, 
VSL#3 might be effective in patients with diarrhea-predominant IBS. In general; however, 
non-targeted investigation of heterogeneous patient populations would tend to diminish the 
ability to identify treatment efficacy. Currently approved therapies for IBS are based on trials 
that are anchored on bowel function phenotype;31 hence, it remains important for future 
trials of VSL#3 in IBS to incorporate phenotypic homogeneity.
In summary, probiotics have generated considerable interest as potential therapeutic agents 
in IBS. However, the biological effects of probiotics may be highly strain-specific and 
careful review of the existing evidence base for specific probiotics strains or combinations of 
strains is important. In our study, VSL#3 was not associated with a clear benefit in 
abdominal pain, stool consistency, abdominal bloating, or quality of life in patients with 
IBS. However, a trend towards improvement in overall response was observed. Notably, 
despite the numerous studies published on VSL#3, studies addressing meaningful outcomes 
of adequate duration of treatment in patients with IBS are limited and the overall quality of 
evidence for three of the five outcomes examined was low. Additional studies of VSL#3 are 
warranted before recommendations regarding its potential efficacy in IBS can be made. Such 
trials should be adequately powered for rigorous clinical endpoints, take into account 
potential biological actions of the specific microbial species included, and have longer 
follow-up in carefully selected patient populations.
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APPENDIX: Detailed Search Strategy
MEDLINE was searched using the OvidSP interface on May 24, 2017
1. exp Colonic Diseases, Functional/ or exp Irritable Bowel Syndrome/
2. exp Probiotics/
3. vsl 3.mp.
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4. vsl #3.mp.
5. 2 or 3 or 4
6. exp Stomach/
7. exp Pain/
8. 6 and 7
9. exp Abdominal Pain/
10. exp Disease Management/ or exp Disease Progression/
11. exp Gastrointestinal Motility/
12. exp Gastric Emptying/
13. exp Remission Induction/ colo
14. exp “Quality of Life”/
15. exp Digestive System/
16. exp Digestive System Physiological Phenomena/
17. exp Diarrhea/
18. exp Treatment Outcome/
19. 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18
20. 1 and 5 and 19
21. limit 20 to (english language and humans)
22. limit 21 to randomized controlled trial
MEDLINE was searched using the PubMed interface on May 24, 2017
(((((((((((((“Treatment Outcome”[Mesh]) OR “Diarrhea”[Mesh]) OR “Digestive System 
Physiological Phenomena”[Mesh]) OR “Digestive System”[Mesh]) OR “Quality of Life”
[Mesh]) OR “Remission Induction”[Mesh]) OR “Gastric Emptying”[Mesh]) OR 
“Gastrointestinal Motility”[Mesh]) OR “Disease Progression”[Mesh]) OR “Disease 
Management”[Mesh]) OR “Abdominal Pain”[Mesh]) OR ((“Pain”[Mesh]) AND “Stomach”
[Mesh]))) AND (((“Colonic Diseases, Functional”[Mesh]) OR “Irritable Bowel Syndrome”
[Mesh])) AND ((“Probiotics”[Mesh]) OR “vsl 3”) OR “vsl #3”
Web of Science was searched on May 25, 2017
# 22 144
#20 AND #19
Refined by: LANGUAGES: ( ENGLISH )
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Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, 
ESCI, CCR-EXPANDED, IC Timespan=All years
# 21 152
#20 AND #19
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, 
ESCI, CCR-EXPANDED, IC Timespan=All years
# 20 176,640
TOPIC: (“randomized controlled trial”)
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, 
ESCI, CCR-EXPANDED, IC Timespan=All years
# 19 527
#18 AND #17 AND #16
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, 
ESCI, CCR-EXPANDED, IC Timespan=All years
# 18 556,498
#15 OR #14 OR #13 OR #12 OR #11 OR #10 OR #9 OR #8 OR #7 OR #6 OR #5
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, 
ESCI, CCR-EXPANDED, IC Timespan=All years
# 17 16,132
#4 OR #3
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, 
ESCI, CCR-EXPANDED, IC Timespan=All years
# 16 18,097
#2 OR #1
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, 
ESCI, CCR-EXPANDED, IC Timespan=All years
# 15 24,302
TOPIC: (“treatment outcome”)
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, 
ESCI, CCR-EXPANDED, IC Timespan=All years
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# 14 62,326
TOPIC: (“diarrhea”)
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, 
ESCI, CCR-EXPANDED, IC Timespan=All year
# 13 4,405
TOPIC: (“digestive system”)
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, 
ESCI, CCR-EXPANDED, IC Timespan=All years
# 12 279,871
TOPIC: (“quality of life”)
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, 
ESCI, CCR-EXPANDED, IC Timespan=All years
# 11 83,178
TOPIC: (“remission” OR “remission induction”)
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, 
ESCI, CCR-EXPANDED, IC Timespan=All years
# 10 10,740
TOPIC: (“gastric emptying”)
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, 
ESCI, CCR-EXPANDED, IC Timespan=All years
# 9 4,669
TOPIC: (“gastrointestinal motility”)
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, 
ESCI, CCR-EXPANDED, IC Timespan=All years
# 8 60,962
TOPIC: (“disease progression”)
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, 
ESCI, CCR-EXPANDED, IC Timespan=All years
# 7 14,723
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TOPIC: (“disease management”)
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, 
ESCI, CCR-EXPANDED, IC Timespan=All years
# 6 32,905
TOPIC: (“abdominal pain”)
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, 
ESCI, CCR-EXPANDED, IC Timespan=All years
# 5 2,727
TOPIC: (“stomach”) AND TOPIC: (“pain”)
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, 
ESCI, CCR-EXPANDED, IC Timespan=All years
# 4 307
TOPIC: (“vsl#3”)
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, 
ESCI, CCR-EXPANDED, IC Timespan=All years
# 3 16,007
TOPIC: (“probiotics”)
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, 
ESCI, CCR-EXPANDED, IC Timespan=All years
# 2 18,096
TOPIC: (“irritable bowel syndrome”)
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, 
ESCI, CCR-EXPANDED, IC Timespan=All years
# 1 3
TOPIC: (“functional colonic disease”)
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, 
ESCI, CCR-EXPANDED, IC Timespan=All years
Scopus was searched on May 25, 2017
( ( ( ”abdominal pain” ) OR ( ”stomach” AND ”pain” ) ) AND ( ( ”abdominal pain” 
OR ”gastric emptying” OR ”gastrointestinal motility” OR ”remission induction” 
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OR ”treatment outcome” OR ”disease progression” OR ”disease management” OR ”quality 
of life” OR ”diarrhea” OR ”digestive system” ) ) ) AND ( ( ”irritable bowel syndrome” 
OR ”colonic diseases, functional” ) AND ( ”probiotics” OR ”VSL#3” ) ) AND ( LIMIT-TO 
( LANGUAGE , ”English” ) ) AND ( EXCLUDE ( DOCTYPE , ”re” ) OR EXCLUDE 
( DOCTYPE , ”ch” ) OR EXCLUDE ( DOCTYPE , ”ed” ) OR EXCLUDE 
( DOCTYPE , ”sh” ) OR EXCLUDE ( DOCTYPE , ”bk” ) OR EXCLUDE 
( DOCTYPE , ”no” ) OR EXCLUDE ( DOCTYPE , ”le” ) ) AND ( LIMIT-TO 
( EXACTKEYWORD , ”Humans” ) OR LIMIT-TO ( EXACTKEYWORD , ”Randomized 
Controlled Trial (topic)” ) ) AND ( LIMIT-TO ( EXACTKEYWORD , ”Randomized 
Controlled Trial” ) )
EMBASE was searching on May 26, 2017
• #8#4 AND #5 AND #6 AND #7 109
• #7’randomized controlled trial’/exp 445466
• #6’irritable bowel syndrome’ 16461
• #5’human’/exp 18195192
• #4#1 AND #2 AND #3 1250
• #3’probiotic agent’/exp OR ‘vsl3’/exp 24570
• #2’irritable colon’/exp 21041
• #1’abdominal pain’/exp OR ‘stomach emptying’/exp OR ‘gastrointestinal 
motility’/exp OR ‘remission’/exp OR ‘treatment outcome’/exp OR 
‘diarrhea’/exp OR ‘disease management’/exp OR ‘disease course’/exp OR 
‘quality of life’/exp OR ‘digestive system’/exp 6002848
Google Scholar was searched on May 26, 2017.
The following strategy was used:
allintitle: irritable bowel syndrome AND “VSL #3”
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KEY POINTS
Studies have indicated a potential benefit of probiotics in IBS, although efficacy of 
individual strains or specific combinations is unknown.
While pooled analyses in the current study show no clear benefit with VSL#3 in IBS on 
abdominal pain or stool consistency, there is a strong trend towards improvement in 
overall response.
Further study of VSL#3 in well-defined IBS patients using validated clinical endpoints is 
required.
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Figure 1: 
Study selection flow diagram
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Figure 2: 
Pooled effects of VSL#3 vs. placebo on abdominal pain reported as standardized mean 
difference
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Figure 3: 
Pooled effects of VSL#3 vs. placebo on stool consistency reported as mean difference
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Figure 4: 
Pooled effects of VSL#3 vs. placebo on overall response reported as risk ratio
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Figure 5: 
Pooled effects of VSL#3 vs. placebo on abdominal bloating reported as standardized mean 
difference
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Figure 6: 
Pooled effects of VSL# vs. placebo on quality of life scores reported as standardized mean 
difference
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Table 1:
Characteristics of included randomized placebo-controlled trials
Study, Year Study Design Location Intervention (dose; N) Control (N) Treatment duration Outcomes reported
Wong et al., 
2015
RCT Singapore, Singapore VSL#3
(450 × 109 LB daily; 
20)
PCBO (22) 6 weeks AP, SC@, AB, 
QOL
Kim et al., 
2005
RCT Rochester, MN VSL#3
(450×109 LB twice 
daily; 24)
PCBO (24) 8 weeks & 4 weeks$ AP, SC, OR, AB
Kim et al., 
2003
RCT Rochester, MN VSL#3
(450 × 109 LB twice 
daily; 12)
PCBO (13) 8 weeks AP, SC, OR, AB
Michail et 
al., 2011
RCT Dayton, OH VSL#3
(900 × 109 LB daily; 
15)
PCBO (9) 8 weeks AP, AB, QOL
Staudacher 
et al., 2016 RCT
& Multi-center* VSL#3(450 × 109 LB twice 
daily; 53)
PCBO (51) 4 weeks AP, SC, OR, AB, 
QOL,
Abbreviations: RCT = randomized controlled trial, PCBO = placebo, LB = lyophilized bacteria, AP = abdominal pain, SC = stool consistency, OR 
= overall response, AB = abdominal bloating, QOL = quality of life
*2 hospitals in London, UK;
@Scale used for stool consistency not provided;
&Study design including four arms (sham diet +PCBO, sham diet + VSL#3, low FODMAP diet + PCBO, low FODMAP diet + VSL#3),
$8 weeks treatment duration for 17 subjects and 4 weeks treatment duration for 31 subjects
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